Alzamend Neuro issues 243,429 common shares on conversion of Series B Preferred (Jul 23-30, 2025)

Alzamend Neuro, Inc.

243,429 common shares issued upon conversion of ~564.76 shares of Series B Convertible Preferred Stock.
Total common outstanding as of July 30, 2025: 3,139,861 shares.
Issuance made in reliance on Section 4(a)(2) exemption from registration.

item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.